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Introduction
A
ccording to the Iranian Welfare Organization 
report,  out  of  a  government-  estimated 
1.8 million drug users in Iran, 9 to16 percent are 
intravenous drug users (IDUs), while half of them 
shared needles (1). Thus, it could be estimated that the 
IDU population in Iran ranges between 200,000 and 
300,000. IDUs are increasing in numbers in Iran and 
constitute an important health problem (2). Hepatitis 
C virus (HCV) is widespread among IDUs in parts 
of  Asia.  The  sharing  of  injection  equipment  and 
imprisonment are the strongest predictors of HCV 
infection in some areas of Asia, such as Iran (1, 3). The 
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Background and Aims: Viral hepatitis is a serious complication among intravenous drug users (IDUs). The objectives of 
this study were to determine the seroprevalence of hepatitis B and C viruses (HBV and HCV), and associated risk factors 
among IDUs at a teaching hospital in Ahvaz, southwest Iran.
Methods: Medical records of 333 IDUs hospitalized from 2002 to 2006 at Razi Hospital, which is affiliated to Ahvaz 
Jundishapur University of Medical Sciences, were reviewed. Cases meeting the criteria for a diagnosis of viral hepatitis 
infection were included in this study. Patients’ characteristics, clinical and laboratory findings were extracted. Data of 
cases with hepatitis virus infection (HVI), called the HVI group and without HVI, called the NHVI group, were compared, 
using the chi-square test for qualitative variables and the t-test for quantitative variables. Differences with a P < 0.05 
were considered significant.
Results: Out of a total of 333 IDUs, 115 (34.5%), mostly male, with a mean age of 24.8±6.2 had HVI. More than 65% 
had a history of imprisonment. The mean duration of IDU was 4.5±1.6 years for the HVI group and 1.8±0.4 years for the 
NHVI group (P < 0.05). 85% of the HVI group and 45% of the NHVI group shared injection equipment (P < 0.05). 103 
patients (30.9%) had HCV and 12 (3.6%) had HBV infection. There was a significant difference in age, duration of drug 
abuse, time spent in prison, sharing injection equipment, history of surgery, blood transfusion, packs of cigarettes per 
year and human immunodeficiency virus (HIV) co-infection between the two groups (P < 0.05).
Conclusions: HVI in IDU population is a prevalent complication, and is associated with heavy smoking (high number of 
packs of cigarettes per year), sharing injection equipment, long duration of drug usage, long duration of prison stay, HIV 
co-infection, history of surgery, blood and blood products transfusion. Older age, longer duration of IDU and imprisonment 
put the cases at higher risk of acquiring HCV in comparison to HBV. 
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prevalence  of  HCV  infection  among  IDUs  varies 
in  different  areas  according  to  socioeconomic  and 
geographical situation as well as HIV infection rate (3, 
4). The transmission of hepatitis B virus(HBV), like 
HCV, is possible in such circumstances as transfusion 
of  unscreened  blood  and  blood  products,  IDU, 
vertically from mother to child, because of needle 
stick, ear piercing, tattoos, barber razors, etc. (5). The 
potential  outcome  of  both  acute  HCV  and  acute 
HBV infection leads to persistent chronic infection, 
cirrhosis,  hepatocellular  carcinoma  and  fulminant 
hepatitis (6). IDUs all over the world not only have 
the highest prevalence of HCV and HBV infection 
but  also  constitute  a  potential  reservoir  of  these 
viruses  in  the  community  (7,  8).  Published  reports 
have described the viral hepatitis as the most common 
infectious diseases among this population (9-17).
The  HCV  and  HBV  infection  rate  in  Iranian 
IDU cases is associated with controversial results (7, 
8, 14, 15). However, as the more common routes of 
transmission for HCV and HBV, such as intravenous 
drug abuse and needle sharing in Iran (7, 15) suggest, 
research  on  viral  hepatitis  is  very  important. The 
present  study  was  performed  to  determine  the 
prevalence and risk factors of HBV and HCV in 
admitted IDU individuals in Ahvaz, a city located in 
southwestern Iran.
Materials and Methods
 The study design was a retrospective file audit.
 Subjects
 Three hundred and thirty-three injecting drug 
users were hospitalized from 2002 to 2006 at Razi 
Hospital, a teaching hospital affiliated to Jundishapur 
University of Medical Sciences in Ahvaz, the capital 
city  of  Khuzestan  province  in  southwestern  Iran. 
These patients were hospitalized due to complaints 
suggestive  of  having  infectious  diseases  such  as 
tuberculosis,  soft  tissue  infection,  osteomyelitis, 
endocarditis etc. Participants included all hospitalized 
IDUs during this period of time and no calculation 
was made for the sample size. Individual files having 
serological viral marker tests such as: antibodies to 
Hepatitis C virus (anti-HCV), hepatitis B surface 
antigen (HBsAg) and antibody to hepatitis B core 
antigen (anti-HBc) were created. Cases that fulfilled 
the diagnostic criteria for hepatitis virus infection 
(HVI)  were  included  in  the  present  study.  Data 
about age, gender, residency, imprisonment, history 
of surgery, blood/blood product transfusion, sharing 
syringes  and  needles,  clinical  findings  suggestive 
of  hepatitis  (e.g.,  icter,  abdominal  pain,  anorexia, 
dark urine, malaise and hepatomegaly), laboratory 
test results of liver biopsy, HCV-RNA-PCR, HCV 
genotyping(if  present)  and  liver  function  tests 
including  aminotransferase;  Alanin  transferase 
(ALT),Asparagine  transferase  (AST)  were  derived 
and recorded. An ALT and an AST of more than 
40  were  defined  as  abnormal  aminotransferase. 
Individuals having at least one of the abovementioned 
serological viral tests with or without clinical findings 
were defined as HVI. HVI cases with abnormal liver 
function tests and clinical findings were defined as 
symptomatic of hepatitis. Patients were placed in two 
groups: the HVI group and (non HVI) the NHVI 
group, and were compared.
Statistical calculation
Data  were  analyzed  by  multivariate  logistic 
regression  to  control  the  impact  of  confounders. 
Student’s t- test was used to compare mean values 
and  the  chi-square  test  was  used  to  compare  the 
proportion between the two different groups in SPSS 
for Windows (version 16; SPSS Inc., USA). Results 
were regarded as significant when P < 0.05. 
Results
Out  of  a  total  of  333  IDU  cases,  115  cases 
(34.5%) with a mean age of 24.8±6.2 (range 20-
52) were diagnosed as having HVI. Out of a total of 
333 IDU cases, 323 (96.9%) were male. According 
to the health profile of these IDU cases registered 
at  the  Khuzestan  Health  Center  (KHC),  more 
than 65% had a history of imprisonment due to 
addiction and its related social behavior. Thirty-five 
percent (documented by KHC), mostly below age 
20 (89%), had a history of HBV vaccination. The 
mean duration of illicit drug use was 4.5±1.6 years 
for the HVI group and 1.8±0.4 years for the NHVI 
group (P < 0.0001).The duration of time spent in 
prison for the HVI and the NHVI group was 6.2 ± 
4.3 years and 2.5±1.8 years, respectively (P<0.0001. 
Eighty-five percent of the HVI group and 45% of 
the NHVI group shared injection equipment (P < 
0.005). One hundred and three patients (30.9%) had 
HCV and 12 (3.6%) had HBV infection. Sixty- two 
(60.1%) with HCV and 4 (33.3%) with HBV were 
symptomatic cases of hepatitis. Five asymptomatic 
cases in the NHVI group had increased ALT and 
AST, among them two patients under treatment with 
anti-tuberculosis drugs. The distribution of patients 
according to gender, age, residency, imprisonment, 
duration  of  intravenous  (IV)  drug  abuse  and 
prison stay, history of surgery, blood/blood product 
transfusion, smoking, cigarette packs per year, co-Hepatitis Monthly, Spring 2010; 10(2): 101-104
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infection with HIV, clinical findings and laboratory 
test results are shown in Table 1.
There  was  no  significant  difference  in  gender, 
imprisonment, smoking and residency between the 
two groups (P > 0.05), but there was a significant 
difference  in  age,  duration  of  drug  abuse,  time 
spent in prison, the sharing of injection equipment, 
history of surgery, blood transfusion, packs smoked 
per year, and HIV co-infection between the two 
groups  (P  <  0.05).  The  final  multiple  logistic 
regression model (chi-square model = 13.11; P = 
0.0001) identified the following as independent risk 
factors for HVI: a longer duration of intravenous 
drug use (odds ratio [OR] 3.1; 95% confidence 
interval [CI] 1.1-8.7) ; sharing in IV equipment 
(OR  1.9;  95%CI  1.2-2.7);  history  of  surgery 
(OR 2.8;95% CI 1.3-5.1); blood transfusion (OR 
3.4;95% CI 1.5-6.2); and HIV co-infection (OR 
4.1;95% CI 1.6-7.1).
Means  of  age,  duration  of  drug  abuse  and 
imprisonment are summarized in Table 2. There was 
a significant difference in age, duration of prison 
stay and drug abuse between patients with hepatitis 
B and patients with hepatitis C (P < 0.05). 
Discussion
In the present study, the seroprevalence rate of 
viral hepatitis among IDUs was 34.5%. In earlier 
studies this rate varies from 1.3% to75 % (18, 19). 
The prevalence of HVI in the IDU population is 
influenced by many factors such as: the seroprevalence 
of the most common viral agents (e.g., HCV and 
HBV) in the community; HBV vaccination coverage; 
public health status; socioeconomic status; and the 
number  of  IDUs  who  share  injection  equipment; 
access to drugs against viral hepatitis; and HIV co-
infection (3).
Hepatitis B prevalence in this study was 3.6%. 
Merat et al. (18), Farhat et al. (19), Sharif et al. (20) 
in their work reported a rate of 1.3%-4%, whereas 
this rate in the Todd et al. (21) work was 6.5%. After 
employment of the HBV vaccination in the Iranian 
National  Program  of  Immunization-Expanded 
Program  of  Immunization  (EPI),  since  1993  the 
prevalence of hepatitis B has decreased throughout 
the country (18, 22). The presence in this study of 
older patients with hepatitis B, in comparison with 
hepatitis C, confirms the efficacy of the high coverage 
of HBV vaccination in those IDU cases who received 
this vaccine in childhood and adolescence.
The prevalence rate of hepatitis C in our study 
was 30.9%. The hepatitis C prevalence rate among 
IDUs  varies  from  10.5%  to  75%  in  published 
studies (20, 23). As mentioned previously, this rate is 
dependent on many factors which vary in different 
areas according to different socioeconomic status and 
health facilities. In this study, hepatitis C was more 
prevalent than hepatitis B. This finding is consistent 
Table 2. Mean of age, duration of drug abuse and 
imprisonment in patients with viral hepatitis in studied 
drug abusers.
Variables 
Hepatitis B
N=12
Hepatitis C
N=103
P-value
Age(year) 26.1 ± 3.9 21.4 ± 5.2 0.02
Drug abuse (year) 3.2 ± 1.8 5.9 ± 2.1 <0.0001
Imprisonment (year) 3.6 ± 3.2 6.7 ± 4.9 0.03
Table 1. Demographic characteristics, epidemiological and other related 
data in studied drug abusers.
Variables 
H-group (n=115)
 N (%)
NH-group (n=218) 
N (%) P-value
Mean age (years) 24.8 ± 6.2 26.3 ± 5.7 0.02
Gender Male 111(96.5) 212(97.2) 0.74
Female  4(3.5) 6(2.8)
Residency Urban 102(88.7) 198(90.8) 0.33
Rural 13(11.3) 20(9.2)
Imprisonment  81(70.4) 136(62.4) 0.14
Cigarette smoker
Mean pack/year
115(100)
17.7 ± 10.4
215(98.6)
11.4 ± 9.6
0.55
<0.0001
History of surgery 15(13.1) 10(4.6) 0.007
Blood transfusion 20(17.4) 11(5.1) 0.0005
Sharing in IV equipment 98(85.2) 98(44.9) <0.0001
HIV co-infection 41(35.6) 19(8.7) <0.0001Hepatitis Monthly, Spring 2010; 10(2): 101-104
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with areas with similar health conditions (20). Indeed, 
HBV vaccination in childhood, the long duration of 
injection drug use, and more time spent in prison 
provides the cases with more exposure to HCV than 
to HBV.
The  present  study  showed  that  viral  hepatitis 
in the IDU population is associated with sharing 
injection equipment, a long duration of drug usage, 
a  long  duration  of  prison  stay,  HIV  co-infection, 
and a history of surgery, blood and blood products 
transfusion. These findings are in agreement with 
some earlier studies and literature (3, 5, 7, 8, 13, 15, 17, 
23). We believe that these variables may be the main 
risk factors for viral hepatitis acquisition in the IDU 
population in the study region.
In our study, viral hepatitis in IDUs is associated 
with  heavy  smoking  (high  number  of  packs  of 
cigarettes per year). We believe that smoking is not 
a  route  of  hepatitis  transmission  but  instead  is  a 
correlate of hepatitis infection among this group.
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